PDS Biotechnology Corporation (PDSB)

Stock Price: $1.67 USD -0.05 (-2.91%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Forbes - 6 days ago

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you t...

Stocks mentioned: BCRX, ECOR, PDSB, TTPH, CRDF
GlobeNewsWire - 1 week ago

NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

GlobeNewsWire - 2 weeks ago

Brazilian government to provide initial funding support to progress development of Versamune®-based vaccine to prevent COVID-19 infection

GlobeNewsWire - 2 weeks ago

FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

GuruFocus - 3 weeks ago

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks ha...

Stocks mentioned: HOTH, PDSB
GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

Seeking Alpha - 1 month ago

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dis...

GlobeNewsWire - 2 months ago

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents NCI to study PDS0103, in addition to planned Phase 2 clinical e...

GlobeNewsWire - 2 months ago

Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration

GlobeNewsWire - 2 months ago

PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies...

Zacks Investment Research - 3 months ago

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 3 months ago

PRINCETON, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Feb. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies ...

Latest From StockTwits